Learning How to Fight Cancer Ep. 7, Pt. 1: Combining Treatments Strategically with Dr. Jay Chaplin
In this two-part episode of Learning How to Fight Cancer, Dr. Matt Halpert sits down with immunologist and immune engineering expert Dr. Jay Chaplin to discuss one of the most overlooked concepts in cancer treatment: timing, context, and coordination within the immune system. Together, they break down why many promising therapies fail in practice, how immunotherapies are often used in the wrong sequence, and why understanding the biology behind treatment combinations matters more than ever.
Dr. Jay shares insights from more than 30 years working in immune engineering, biologics, vaccine design, autoimmunity, and advanced cancer therapeutics. The conversation explores checkpoint inhibitors, dendritic cell therapies, inflammation, supplements, immune signaling, and why many cancer approaches may conflict when used without a strategic framework.
This discussion is designed to help patients, caregivers, and practitioners better understand how immune-based therapies actually work inside the body — and why “more” treatment is not always better treatment.
Stay tuned for even more insights in Part 2.
Show Notes / Timestamps:
00:00 – Why immune responses depend on timing, order, and context
00:39 – Introduction to Dr. Jay Chaplin and immune engineering
02:15 – Helping patients navigate misinformation and conflicting therapies
03:23 – The dangers of “doing everything” without strategy
04:45 – Why in vitro cancer studies often fail in real patients
05:47 – The problem with cancer information online
06:55 – Experimental therapies vs. practical patient strategies
07:09 – Why every cancer and immune response is unique
08:45 – Curcumin, inflammation, and unintended immune suppression
09:18 – Checkpoint inhibitors explained: CTLA-4, PD-1, TIGIT
11:12 – Why immunotherapy timing matters
12:08 – Concerns about how oncology currently uses immunotherapies
14:35 – Why dendritic cell placement is critically important
16:24 – Why cancer treatment innovation moves so slowly
17:01 – Lessons from the history of immunotherapy and William Coley
19:00 – Why immunologists and oncologists should work together
21:10 – Building strategic treatment stacks instead of random combinations
READ THIS NEXT
On Air with Immunocine: Dr. Matt Halpert Discusses the Future of Dendritic Cell Immunotherapy on The Moss Report
Matt Halpert, PhD, recently joined Ben Moss and Ralph W. Moss, PhD, on The Moss Report for a wide-ranging conversation about dendritic cell
Read More
Life After Cancer: Hope’s Stage 4 Breast Cancer Story
Hope and her husband, Phil, were looking forward to retirement and beginning a new chapter together. They talked about spending more time on
Read More
How a Discovery in the Lab Became a New Approach to Cancer Treatment
Every medical innovation has an origin story. For Immunocine, that story begins not in a clinic, but in a research laboratory. In this video
Read More
